Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah, Rui‐Hua Xu, Ahsan M. Arozullah et al.|Nature Medicine|2023

Cited by 541